Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors at 10 institutions in 1 country.
Jung-Joon ChaDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0002-8299-1877
Jae Young ChoDivision of Cardiology, Department of Internal Medicine, Regional Cardiocerebrovascular Center Wonkwang University Hospital Iksan Republic of Korea.ORCID 0000-0001-7972-6223
Subin LimDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0003-4660-8911
Ju Hyeon KimDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0002-4193-0891
Hyung Joon JooDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0003-1846-8464
Jae Hyoung ParkDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.
Soon Jun HongDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0003-4832-6678
Do-Sun LimDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0001-5751-5177
Hyungdon KookDivision of Cardiology, Department of Internal Medicine College of Medicine, Hanyang University Seoul Republic of Korea.ORCID 0000-0003-1440-0462
Seung Hun LeeCardiovascular Center Donggunsan Hospital Gunsan Republic of Korea.ORCID 0000-0002-5154-1697
Young-Guk KoDivision of Cardiology, Department of Internal Medicine Severance Cardiovascular Hospital, Yonsei University College of Medicine Seoul Republic of Korea.ORCID 0000-0001-7748-5788
Pil-Ki MinDivision of Cardiology, Department of Internal Medicine Gangnam Severance Hospital, Yonsei University College of Medicine Seoul Republic of Korea.ORCID 0000-0001-7033-7651
Jae-Hwan LeeDivision of Cardiology, Department of Internal Medicine Chungnam National University Hospital Daejeon Republic of Korea.ORCID 0000-0002-6561-7760
Chang-Hwan YoonDivision of Cardiology Department of Internal Medicine Seoul National University Bundang Hospital Seongnam Republic of Korea.ORCID 0000-0001-6305-4442
In-Ho ChaeDivision of Cardiology Department of Internal Medicine Seoul National University Bundang Hospital Seongnam Republic of Korea.ORCID 0000-0003-1644-2105
Seung Whan LeeDivision of Cardiology, Department of Internal Medicine, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea.ORCID 0000-0002-2662-5952
Sang-Rok LeeDivision of Cardiology, Department of Internal Medicine Chonbuk National University Hospital Jeonju Republic of Korea.ORCID 0000-0002-5845-2232
Seung Hyuk ChoiDivision of Cardiology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea.ORCID 0000-0002-0304-6317
Yoon Seok KohDivision of Cardiology Department of Internal Medicine Hallym University Sacred Heart Hospital Seoul Republic of Korea.
Cheol Woong YuDivision of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.ORCID 0000-0002-5871-4562
Korea University Medical Center · KRUlsan College · KRKorea University · KRSeoul National University Bundang Hospital · KRYonsei University · KRChungnam National University Hospital · KRHallym University Sacred Heart Hospital · KRHanyang University · KRSamsung Medical Center · KRWonkwang University · KR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background No large-scale study has compared the clinical impact of triple antiplatelet therapy (TAPT: aspirin, clopidogrel, and cilostazol) and dual antiplatelet therapy (DAPT) on adverse limb events in patients with diabetes after endovascular therapy (EVT) for peripheral artery disease. Thus, we investigate the effect of cilostazol added to a DAPT on the clinical outcomes after EVT in patients with diabetes using a nationwide, multicenter, real-world registry. Methods and Results A total of 990 patients with diabetes who underwent EVT were enrolled from the retrospective cohorts of a Korean multicenter EVT registry and were divided according to the antiplatelet regimen (TAPT [n=350; 35.4%] versus DAPT [n=640; 64.6%]). After propensity score matching based on clinical characteristics, a total of 350 pairs were compared for clinical outcomes. The primary end points were major adverse limb events, a composite of major amputation, minor amputation, and reintervention. For the matched study groups, the lesion length was 125.4±102.0 mm, and severe calcification was observed in 47.4%. The technical success rate (96.9% versus 94.0%;
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease. · full record | OpenQuestion